Nvidia's new $999 card earned our Editors' Choice award on the basis of its pure muscle, but I have a few very specific ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term. Read why MEDP stock is a Strong Buy.

In general, Amazon's approach is to be everything to everyone rather than striving for a niche audience, and it has released ...